Biologics
Harbour BioMed Secures China’s NMPA Approval for Batoclimab, Expanding Treatment Options for Myasthenia Gravis
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics i...
October 26, 2026 | News
Coreline Soft Secures 13th US FDA Clearance, Expanding AI-Powered CT Imaging into Aortic Assessment
Secures its 13th FDA 510(k) clearance, expanding its U.S. portfolio from lung nodule detection and coronary artery calcium (CAC) analysis to quanti...
October 26, 2026 | News
Zai Lab’s Zoci–Atezolizumab Combination Delivers 81.8% Response Rate in First-Line Small Cell Lung Cancer
At the recommended Phase 3 dose (RP3D) of 1.6 mg/kg, zoci plus atezolizumab achieved a confirmed objective response rate of 81.8% (27/33) and an est...
October 26, 2026 | News
Lunit and Summit Therapeutics Join Forces to Decode Tumour Biology with AI-Powered Pathology
Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Bi...
October 26, 2026 | News
Akeso and Summit Advance Ivonescimab into Seventh Global Registrational Trial Targeting Biliary Tract Cancer
Akeso, Inc. announced that Summit Therapeutics Inc. (NASDAQ: SMMT), its global partner for ivonescimab, has entered into a clinical trial collaboration wit...
October 23, 2026 | News
Geneos Launches Global Phase 2 Trial of Personalised Cancer Vaccine to Prevent Liver Cancer Recurrence
Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of neoantigen-based personalized immunotherapy for cancer (PIC), a...
October 23, 2026 | News
Therakos Secures EU MDR Approval for First-of-Its-Kind Therapy to Manage Cancer Immunotherapy Toxicities
Therakos Development Limited, a global pioneer in immunomodulatory therapy delivered at the bedside through extracorporeal photopheresis (ECP), announced t...
October 23, 2026 | News
Merck to Acquire Silence Therapeutics for $1.3 Billion, Expanding Rare Disease Portfolio with siRNA Innovation
Purchase price of $20 per ADS in cash represents an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion Silence Therapeut...
October 22, 2026 | News
Metabolon Launches AI-Enabled Splash & Ripple to Accelerate Metabolomics-Driven Drug Discovery
New bioinformatics application combines curated metabolite-protein knowledge, advanced network algorithms, interactive exploration, and optional AI interpr...
October 22, 2026 | News
Ascletis Reports Promising Preclinical Data for Once-Weekly Oral Obesity Treatments, Advances US Phase 1 Trial
Ascletis' industry-leading once-weekly oral peptide pipeline covers all four validated targets, with multiple first-in-class fixed-dose combina...
October 21, 2026 | News
Chipscreen Biosciences Secures China IND Approval for First-in-Class Cancer Immunotherapy NW001
Shenzhen Chipscreen Biosciences Co., Ltd. announced that NW001, a first-in-class epigenetic immune-modulating antibody conjugate (EIMAC) co-developed with ...
October 21, 2026 | News
Telix and Ekalia Join Forces to Scale Astatine-211 Production for Next-Generation Cancer Therapies in the US
Collaboration establishes a framework for a dedicated U.S. source of astatine-211 (211At), a scarce, next-generation alpha-emitting isotope with signific...
October 20, 2026 | News
Brii Biosciences Unveils Dual-Targeting siRNA Platform to Advance Next-Generation RNA Therapeutics
Proprietary BRiSC™ platform to advance the discovery and development of next-generation dual-targeting siRNA medicines Initial focus on prevalent me...
October 19, 2026 | News
NueCell Bio Joins CIRM Partnership to Accelerate Cell and Gene Therapies from Discovery to GMP Readiness
NueCell Bio, a translational development partner that helps advance cell therapies from scientific discovery to GMP readiness, announced it has joined the ...
October 16, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
